88
Participants
Start Date
May 28, 2018
Primary Completion Date
March 6, 2019
Study Completion Date
March 6, 2019
SAD: APX-115
Drug: APX-115 SAD APX-115 SAD for 1day
SAD: Placebo
Drug: Placebo Placebo for 1day
MAD: APX-115
Drug: APX-115 MAD APX-115 MAD repeatedly administered.
MAD: Placebo
Matching study drug will be repeatedly administered.
Food effect: fasted and fed
A single dose of APX-115, selected from the SAD study, will be administered under fasted and fed condition.
Metabolic probe with or without APX-115
A metabolic probe will be administered with and without APX-115.
Eurofins Optimed, Gières
Lead Sponsor
Aptabio Therapeutics, Inc.
INDIV